









Markets
/
Stocks
/
nasdaq-ndra
/

ENDRA Life Sciences Inc

NDRA

4.990USD

-0.180-3.48%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

3.75MMarket Cap

LossP/E TTM



ENDRA Life Sciences Inc

4.990

-0.180-3.48%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of ENDRA Life Sciences Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

ENDRA Life Sciences Inc's Score

Industry at a Glance

Industry Ranking

208 / 407

Overall Ranking

367 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

38.000

Target Price

+635.01%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

ENDRA Life Sciences Inc Highlights

StrengthsRisks

ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology which characterizes tissue similar to a magnetic resonance imaging (MRI). The Company's TAEUS technology uses radio frequency (RF) pulses to stimulate tissues, using a small fraction (less than 1%) of the amount of energy that would be transmitted into the body during an MRI scan. The use of RF energy allows its TAEUS technology to penetrate deep into tissue, enabling the imaging of human anatomy at depths equivalent to those of conventional ultrasound. The RF pulses are absorbed by tissue and converted into ultrasound signals. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease (SLD), a chronic liver disease spectrum. It is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.

Overvalued

The company’s latest PE is 0.01, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 12.68K shares, increasing 16.51% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.82K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 7.15, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.15

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.95

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

ENDRA Life Sciences Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 6.62, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is 0.01, which is 76.80% below the recent high of 0.02 and 8857.60% above the recent low of -1.09.

Score

Industry at a Glance

Previous score

6.62

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 208/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 8.00, which is equal to the Biotechnology & Medical Research industry's average of 8.00. The average price target for ENDRA Life Sciences Inc is 38.00, with a high of 38.00 and a low of 38.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Buy

Current Rating

38.000

Target Price

+635.01%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

ENDRA Life Sciences Inc

NDRA

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 1.29, which is lower than the Biotechnology & Medical Research industry's average of 6.41. Sideways: Currently, the stock price is trading between the resistance level at 8.37 and the support level at 3.10, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

1.28

Change

0.01

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.303

Sell

RSI(14)

43.030

Neutral

STOCH(KDJ)(9,3,3)

41.110

Buy

ATR(14)

0.484

Low Volatility

CCI(14)

-58.476

Neutral

Williams %R

86.195

Oversold

TRIX(12,20)

-0.454

Sell

StochRSI(14)

41.864

Sell

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

5.060

Sell

MA10

5.110

Sell

MA20

5.947

Sell

MA50

5.270

Sell

MA100

5.202

Sell

MA200

4.723

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.15. The latest institutional shareholding proportion is 1.09%, representing a quarter-over-quarter decrease of 63.66%. The largest institutional shareholder is The Vanguard, holding a total of 2.82K shares, representing 0.24% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

DiGiandomenico (Anthony)

5.44K

+9125.42%

Geode Capital Management, L.L.C.

5.13K

+13.09%

UBS Financial Services, Inc.

4.70K

The Vanguard Group, Inc.

Star Investors

116.00

S.H.N. Financial Investments Ltd

686.00

Northwestern Mutual Capital, LLC

35.00

Thornton (Michael Milos)

20.00

BofA Global Research (US)

6.00

+50.00%

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 1.58, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is -0.31. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.